



CEOcast, Inc.
James Young
Investor Relations
Tel: 212-732-4300
Email: jyoung@ceocast.com

ImmunoCellular Therapeutics to Present at the 13th Annual Rodman & Renshaw Global Investment Conference on September 13th



LOS ANGELES, Sep 09, 2011 (BUSINESS WIRE) -- ImmunoCellular Therapeutics, Ltd. (otc.bb:IMUC), a biotechnology company focused on the development of novel immune-based cancer therapies, announced today that the company will present at the Rodman & Renshaw 13th Annual Global Investment Conference at the Waldorf Astoria in New York City on September 13th. The presentation will be given at 9:10 a.m. Eastern Daylight Time in Starlight South room.

The Company's presentation will be webcast at: <http://wsw.com/webcast/rrshq20/imuc.ob>

About ImmunoCellular Therapeutics, Ltd.

IMUC is a Los Angeles-based clinical-stage company that is developing immune-based therapies for the treatment of brain and other cancers. The Company recently commenced a Phase II trial of its lead product candidate, ICT-107, a dendritic cell-based vaccine targeting multiple tumor associated antigens for glioblastoma. To learn more about IMUC, please visit www.imuc.com

Forward-Looking Statements

This press release contains certain forward-looking statements that are subject to a number of risks and uncertainties, including without limitation the need for substantial additional capital to fund development of product candidates beyond their initial clinical or pre-clinical stages; the risk that the safety and efficacy results obtained in the Phase I trial for the dendritic cell-based vaccine will not be confirmed in subsequent trials; the

risk that the correlation between immunological response and progression-free and overall survival in the Phase I trial for ICT-107 will not be reflected in statistically significant larger patient populations; the risk that IMUC will not be able to secure a partner company for development or commercialization of ICT-107; the need to satisfy performance milestones to maintain the vaccine technology licenses with Cedars-Sinai; the risks associated with adhering to projected preclinical or clinical timelines and the uncertainties of outcomes of development work for product candidates; and the risk of obtaining patent coverage for the dendritic cell-based vaccine or that any patents covering this vaccine will provide commercially significant protection for this product candidate. Additional risks and uncertainties are described in IMUC's most recently filed SEC documents, such as its most recent annual report on Form 10-K, all quarterly reports on Form 10-Q and any current reports on Form 8-K. IMUC undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

SOURCE: ImmunoCellular Therapeutics, Ltd.